Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

BACKGROUND: Patients with resistant primary focal segmental glomerulosclerosis (FSGS) are at high risk of progression to chronic kidney disease stage V. Antifibrotic agents may slow or halt this process. We present outcomes of follow-up after a Phase I trial of adalimumab and rosiglitazone, antifibr...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Peyser, Alexandra, MacHardy, Nathaniel, Tarapore, Freya, MacHardy, Jacqueline, Powell, Leslie, Gipson, Debbie S, Savin, Virginia, Pan, Cynthia, Kump, Theresa, Vento, Suzanne, Trachtman, Howard
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2010
Sujets:
Research article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2823728/
https://ncbi.nlm.nih.gov/pubmed/20113498
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2369-11-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires